TickerTalks
Browse all tickers →
TickerTalks›$MGNX
MGMGNX

MacroGenics, Inc.

$MGNX·$275M·Biotechnology·Healthcare
$4.32+0.7%YTD+168.3%1Y+189.9%
Mentions · last 7 days
2026-07-09: 1 posts2026-07-10: 2 posts2026-07-11: 1 posts2026-07-12: 1 posts2026-07-13: 3 posts2026-07-14: 1 posts2026-07-15: 2 posts11+30%
Price updated 7h ago·X counts updated 7h ago
MGMGNX
$MGNXMacroGenics, Inc.
$4.32+0.70%11 posts+30%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $MGNX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-07-15

The move is getting stronger, with heavier trading behind it.

MacroGenics up 166% YTD on TZIELD milestones plus GMP-facility sale — real cash from real approvals.

MacroGenics is a small-cap ADC and bispecific-antibody biotech that has caught its first genuine tailwind in years.

  • Real royalty cash: Sanofi's TZIELD (teplizumab, originally partnered from MacroGenics) received a fresh regulatory approval driving a milestone payment; the pipeline framework points to a ~$30M near-term milestone and a path to ~$275M in aggregate future sales-milestones plus tail royalties on a first-in-class T1D disease-modifying drug.
  • Portfolio simplification: Jul 2 completed sale of the GMP manufacturing / CDMO business to Bora Pharmaceuticals (Taiwan) and Bora Biologics USA on June 30 — non-strategic disposition that concentrates the company on drug-development.
  • Revenue is volatile — Q1 2026 $20.8M (+57.5% YoY), Q4 2025 +133%, Q3 -34%, Q2 +106% — royalty and milestone timing drives quarterly swings, so trend more than any single print.
  • Operating margin -161% in Q1 despite 46% gross margin — the burn is real; cash runway commentary matters.
  • Governance: Director Karen Ferrante resigned July 8 effective September 1 for personal reasons; no disagreement cited.
  • Setup: $4.29, +166% YTD, +171% over 12 months, sitting 79% up 52-week range and 67% above 200-day MA — the re-rating has already run.
  • Key upcoming catalyst is the MGC026 mid-year data readout referenced in bullish sentiment.

Aug 13 Q2 print — TZIELD milestone timing and cash runway will drive the near-term tape.

Agrees with X sentimentX sentiment aligns — TZIELD $30M milestone framing, pipeline of three additional FDA-approval-eligible assets, ADC acquisition-target framing, MGC026 midyear readout expected. Consistent with the tape.

What to watch: Aug 13 Q2 print — TZIELD milestone recognition timing, GMP-sale cash inflow and use, cash runway; MGC026 midyear data readout; lorigerlimab Phase 2 data (mCRPC bispecific); further Sanofi TZIELD sales milestones.

On the calendar: 2026-08-13 — Q2 2026 earnings (EPS est +$0.03)

micro caproyalty dependent

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-06-18

MacroGenics' originally-licensed drug just got approval as the first T1D disease-modifying drug, triggering an expected $30M regulatory milestone and clearer path to $275M in sales milestones plus tail royalties. Three additional FDA-approval-eligible assets remain in the pipeline. New management is described as improving clinical-trial selection, framing MGNX as a top US ADC acquisition target with the MGC026 midyear readout pending. One investor closed a 200% trade.

Read the AI verdict + X sentiment for $MGNX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops bispecific and Fc-optimized antibody cancer therapies; lead program vobramitamab duocarmazine targets solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MGNX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $MGNX

Partial — Develops bispecific and Fc-optimized antibody cancer therapies; lead program vobramitamab duocarmazine targets solid tumors; exposure exists but is diluted by diverse end markets and revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+47.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-40.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-148%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 13, 2026$-0.58$-0.57-1.8%
Q4 2025Mar 9, 2026$-0.22$-0.42+47.6%
Q3 2025Nov 12, 2025$0.27$-0.48+156.3%
Q2 2025Aug 14, 2025$-0.57$-0.59+3.4%
Next earningsThu, Aug 13·consensus EPS $0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$20.8M+57.5%46.0%-161%$-0.58$-36.2M
Q4 FY25$41.2M+132.5%71.3%-29.3%$-0.22$42.8M
Q3 FY25$72.8M-34.2%81.6%25.6%$0.27$-30.6M
Q2 FY25$22.2M+106.0%51.4%-165%$-0.57$-47.7M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$151.5M$114.0M – $189.0M-$0.91-$1.46 – -$0.343
FY27$102.8M$79.7M – $125.9M-$1.23-$1.59 – -$0.874
FY28$172.5M$112.2M – $231.1M-$1.29-$2.19 – -$0.643
FY29$226.4M$147.3M – $303.4M-$0.86-$1.25 – -$0.472
FY30$303.7M$197.5M – $406.9M-$0.27-$0.38 – -$0.141

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.80%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+67.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 52.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.185-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 27 other (12 awards · 12 exempts · 3 inkinds) in window

See when $MGNX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 88-K — Item 5.02: Officer or director change
AI summary

MacroGenics announced that director Karen Ferrante, M.D., has resigned from the Board of Directors effective September 1, 2026, citing personal reasons. Her departure was not due to any disagreement with management or the board on matters of company operations, policies, or practices. The company will evaluate whether to replace her seat, though no immediate plans for a new director appointment were disclosed in this filing.

8-KAcquisition completedJul 78-K — Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

MacroGenics, Inc. completed the sale of its GMP manufacturing and CDMO business to Bora Pharmaceuticals Co., Ltd. (Taiwan) and Bora Biologics USA, LLC on June 30, 2026, pursuant to an Asset Purchase Agreement signed May 11, 2026. The purchase price was $122.5 million before transaction fees and subject to customary post-closing adjustments. Bora assumed responsibility for the CDMO operations at the Rockville, Maryland facility and the Frederick, Maryland warehouse. This is a strategic asset divestiture that enables MacroGenics to focus on its drug pipeline while generating $122.5 million in proceeds.

8-KShareholder voteMay 208-K — Item 5.07: Shareholder vote
AI summary

MacroGenics, Inc. (MGNX) filed an 8-K on May 19, 2026 disclosing annual shareholder meeting vote results (Item 5.07). MacroGenics is a Rockville, Maryland-based clinical-stage biopharmaceutical company listed on Nasdaq. Annual meeting results are routine governance disclosures.

8-KMaterial agreementMay 128-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

MacroGenics Inc. (MGNX) filed an 8-K covering two items: a material definitive agreement (Item 1.01) and a Regulation FD disclosure (Item 7.01). The company entered into a new collaboration or licensing arrangement and simultaneously disclosed related information to ensure fair public access. The agreement may involve milestone payments, royalties, or co-development rights with a strategic partner. Full agreement details and any investor presentation materials are filed as exhibits.

8-KMaterial agreementMay 48-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

MacroGenics Inc. (MGNX) filed an 8-K disclosing a new material definitive agreement (Item 1.01) alongside other material events (Item 8.01). The clinical-stage biopharmaceutical company entered into a collaboration, licensing, or supply agreement with strategic or financial terms material to the business. The Item 8.01 may cover related announcements or developments tied to the agreement. Full agreement terms are included as exhibits to the filing.

+ 17 other (7 13Gs · 3 proxys · 3 routine 8-Ks · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?zacks.com·14d agoMacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticalsglobenewswire.com·14d agoMacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approvalglobenewswire.com·24d agoMacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forumglobenewswire.com·63d agoMacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimateszacks.com·63d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$ALLO
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport